Skip to main content

14 Result(s)

within H. Wandt Remove this filter Medicine/Public Health, general Remove this filter

and

  1. No Access

    Article

    Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma

    H Einsele, S Knop, M Vogel, J Müller, M Kropff, B Metzner, C Langer, H Sayer… in Leukemia (2017)

  2. No Access

    Article

    Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning

    An alternative reduced-toxicity conditioning regimen for allogeneic transplantation, based on treosulfan and fludarabine, has recently been identified. The safety and efficacy of this new conditioning regimen ...

    J Casper, J Holowiecki, R Trenschel, H Wandt… in Bone Marrow Transplantation (2012)

  3. No Access

    Article

    A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT

    We compared the efficacy and safety of empirical plus PCR-based vs empirical liposomal amphotericin B treatment after Allo-SCT. Allo-SCT recipients were randomized to receive either PCR-based preemptive therap...

    H Hebart, L Klingspor, T Klingebiel, J Loeffler, J Tollemar… in Bone Marrow Transplantation (2009)

  4. No Access

    Article

    The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

    Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves trea...

    C Buske, E Hoster, M Dreyling, H Eimermacher, H Wandt, B Metzner, R Fuchs… in Leukemia (2009)

  5. No Access

    Article

    AML1–ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia

    F Schneider, S K Bohlander, S Schneider, C Papadaki, P Kakadyia, A Dufour… in Leukemia (2007)

  6. No Access

    Article

    A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation

    Prophylactic platelet transfusions are considered as standard in most hematology centers, but there is a long-standing controversy as to whether standard prophylactic platelet transfusions are necessary or whe...

    H Wandt, K Schaefer-Eckart, M Frank, J Birkmann, M Wilhelm in Bone Marrow Transplantation (2006)

  7. No Access

    Article

    Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

    We analyzed the incidence, presenting features, risk factors of extramedullary (EM) relapse occurring in acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) and chemotherapy by using a ...

    S de Botton, M A Sanz, S Chevret, H Dombret, G Martin, X Thomas, J D Mediavilla… in Leukemia (2006)

  8. No Access

    Article

    High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)

    The majority of advanced ovarian cancer patients achieve an objective response following chemotherapy; however, only 20–30% are in remission after 5 years. Intraperitoneal or high-dose chemotherapy (HDC) may p...

    C Bengala, V Guarneri, J Ledermann, G Rosti, H Wandt… in Bone Marrow Transplantation (2005)

  9. No Access

    Article

    First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party

    Extragonadal germ cell tumors are classified according to the staging system of the International Germ Cell Cancer Collaborative Group (IGCCCG). The 5-year overall and disease-free survival rates for poor prog...

    G Rosti, U De Giorgi, H Wandt, B Lioure, S Leyvraz, K Kolbe… in Bone Marrow Transplantation (2004)

  10. No Access

    Article

    Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients

    The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based ...

    N Kröger, L Damon, A R Zander, H Wandt, G Derigs, P Ferrante… in Bone Marrow Transplantation (2003)

  11. No Access

    Article

    Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

    The feasibility of nonmyeloablative stem cell transplantation (NST) was evaluated in 22 adults with high-risk ALL. 16/22 patients had advanced disease and 11/22 had Ph+ ALL. Eleven patients received NST as fir...

    R Arnold, G Massenkeil, M Bornhäuser, G Ehninger, DW Beelen, AA Fauser… in Leukemia (2002)

  12. No Access

    Article

    Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation

    Transplantation with histocompatible identical siblings is a curative treatment for patients with myelodysplastic syndromes (MDS). Alternative treatments, such as transplantation with other family donors, are ...

    T de Witte, F Pikkemaat, J Hermans, A van Biezen, S Mackinnan, J Cornelissen… in Leukemia (2001)

  13. No Access

    Article

    Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia

    First results of a randomized trial (APL91 trial) and other randomized or non-randomized studies have shown that ATRA followed by chemotherapy significantly increased event-free survival (EFS) and survival, an...

    P Fenaux, S Chevret, A Guerci, N Fegueux, H Dombret, X Thomas, M Sanz, H Link… in Leukemia (2000)

  14. No Access

    Article

    Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer

    To assess high-dose carboplatin chemotherapy with or without paclitaxel with filgrastim mobilized peripheral blood progenitor cell (PBPC) support in a phase I/II study, a total of 21 patients with mostly chemo...

    H Wandt, J Birkmann, Th Denzel, K Schäfer, G Schwab, D Pilz… in Bone Marrow Transplantation (1999)